Hyperion raises $60M to battle urea cycle disorders
Hyperion Therapeutics, developer of treatments for urea cycle disorders and illnesses, has brought in $60 million in a third round of financing from Bay City Capital, Panorama Capital, Highland Capital Partners, New Enterprise Associates and Sofinnova Ventures.
Based in South San Francisco, the company recently completed phase-two clinical trials for its lead drug candidate and says the new capital will be used to push it through phase three. This therapy is targeted at patients who are born without enough of a certain enzyme in their urea cycles, a condition that can lead to dangerously high levels of ammonia in the bloodstream.
Some of the money will also be used for a phase-two study looking at hepatic encephalopathy (a neurological disorder that occurs in patients with liver failure).
Hyperion previously raised a $40 million second round of venture funding and an undisclosed amount in a first round.
Next Story: SPG Holdings brings in $13 million for solar projects
Previous Story: Baby boomer social network TeeBeeDee implodes
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.